SCHOTT Pharma jumps after Q3 revenue beat, guidance hike

SCHOTT Pharma AG & Co. KGaA

09/07/2026 09:36

** Shares in SCHOTT Pharma 1SXP.DE rise 15.5% after the German medical equipment supplier published on Thursday after market close its preliminary Q3 2026 figures and raised its FY guidance
** SCHOTT expects Q3 constant-currency revenue growth of about 8%, ahead of Vara consensus expectations of 3.5%
** It now guides for full-year constant-currency revenue growth of 5%-6%, up from its previous forecast of 2%-5% and above market expectations of 3.2%
** The hike is supported by "strong business performance", expectations for Q4 and an agreement with a key customer for glass syringes, the company said
** Brokerage RBC says Schott's Q3 release shows evidence of a continuing recovery, and ups rating to "outperform" from "sector perform"
** Including today's rise, the stock has gained 34.77% YTD
     

(Reporting by Basile Day)
((Basile.Day@thomsonreuters.com))